Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BMS, Tibotec to target HCV
January 2012
SHARING OPTIONS:

NEW YORK—Bristol- Myers Squibb Co. (BMS) recently announced the establishment of a clinical collaboration agreement with Tibotec Pharmaceuticals, one of the Janssen Pharmaceuticals companies, to study the utility of daclatasvir, BMS' investigational NS5A replication complex inhibitor, in combination with Tibotec's investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV). Per the agreement, BMS and Tibotec will evaluate the potential of three treatment regimens to achieve sustained viral response 12 and 24 weeks post treatment in patients with HCV genotype 1. The oral regimens will include a once-daily treatment of daclatasvir and TMC 435 pegylated-interferon alpha plus ribavirin, a once-daily treatment of daclatasvir and TMC435 with ribavirin and a once-daily treatment of daclatasvir and TMC435 alone. The study is anticipated to begin in the first half of 2012.


Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.